VERU is up about 200% on a very questionable trial of only 150 patients. Placebo had a mortality rate of 45% which makes no sense. If VERU can go up 200% on trial results that have virtually no chance at getting an EUA then HGEN might go up 2,000% if/when it gets stat sig for a second time.
The primary endpoint population of the ACTIV trial are patients with a CRP<150mg/L + <85yo + on remdesivir. That population had 243% efficacy in the LIVE-AIR trial on the primary endpoint. Stat sig in the ACTIV trial is a given on the primary endpoint. Stat sig on mortality is a real possibility. The LIVE-AIR had stat sig on mortality with the 336 patients with CRP<150mg/L and <85yo. There is still no effective treatment for newly hospitalized patients. Lenzilumab is a game-changer. Data will be our savior.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.